tiprankstipranks
Trending News
More News >
MedAdvisor Limited (AU:MDR)
ASX:MDR
Australian Market

MedAdvisor Limited (MDR) AI Stock Analysis

Compare
16 Followers

Top Page

AU

MedAdvisor Limited

(Sydney:MDR)

Rating:53Neutral
Price Target:
AU$0.00
▼(-100.00%Downside)
MedAdvisor Limited shows strong financial performance with significant revenue and cash flow growth, contributing positively to the score. However, bearish technical indicators and a poor valuation due to negative earnings weigh heavily, resulting in a moderate overall stock score. Continued financial improvements and a reversal in market sentiment could enhance future prospects.

MedAdvisor Limited (MDR) vs. iShares MSCI Australia ETF (EWA)

MedAdvisor Limited Business Overview & Revenue Model

Company DescriptionMedAdvisor Limited (MDR) is a healthcare technology company that specializes in medication management solutions. It operates primarily within the digital health and pharmaceutical sectors, providing platforms that enhance patient engagement and health outcomes through improved medication adherence. MedAdvisor's core services include a mobile and web app that allows patients to manage their medication schedules, receive reminders, and connect with healthcare providers and pharmacies.
How the Company Makes MoneyMedAdvisor Limited generates revenue through a combination of B2B and B2C models. The company primarily earns money by offering subscription-based services to pharmacies and healthcare providers who utilize its platform to enhance patient engagement and ensure medication adherence. Additionally, MedAdvisor forms partnerships with pharmaceutical companies, providing them with data analytics and patient engagement tools which can help in marketing and adherence programs. Revenue is also derived from licensing fees and custom solutions tailored to specific client needs, as well as potential commissions from e-commerce transactions facilitated through its platform. Strategic partnerships and collaborations with healthcare stakeholders further contribute to its financial performance.

MedAdvisor Limited Financial Statement Overview

Summary
Income Statement
Balance Sheet
Cash Flow
Breakdown
Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
122.11M97.96M67.75M38.77M9.60M
Gross Profit
23.63M12.59M-1.84M-6.06M-3.63M
EBIT
2.70M-7.72M-16.19M-18.31M-11.13M
EBITDA
7.05M-3.03M-11.29M-14.93M-10.34M
Net Income Common Stockholders
792.13K-11.31M-17.35M-13.95M-9.58M
Balance SheetCash, Cash Equivalents and Short-Term Investments
15.58M14.20M7.58M7.15M12.35M
Total Assets
98.78M95.91M78.44M80.92M21.27M
Total Debt
12.61M13.09M13.41M9.16M1.42M
Net Debt
-2.97M-1.11M5.84M2.01M-10.92M
Total Liabilities
47.20M47.45M43.89M32.07M4.25M
Stockholders Equity
51.58M48.46M34.55M48.45M16.66M
Cash FlowFree Cash Flow
3.35M-1.63M-548.13K-12.94M-9.00M
Operating Cash Flow
5.19M-1.45M-236.32K-12.54M-8.68M
Investing Cash Flow
-2.80M-3.23M-290.79K-43.36M230.68K
Financing Cash Flow
-831.97K12.42M1.86M50.72M16.39M

MedAdvisor Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.08
Price Trends
50DMA
0.10
Negative
100DMA
0.13
Negative
200DMA
0.23
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
36.38
Neutral
STOCH
-14.90
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MDR, the sentiment is Negative. The current price of 0.08 is below the 20-day moving average (MA) of 0.09, below the 50-day MA of 0.10, and below the 200-day MA of 0.23, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 36.38 is Neutral, neither overbought nor oversold. The STOCH value of -14.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:MDR.

MedAdvisor Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AUADH
73
Outperform
AU$482.51M14.5814.57%5.45%0.49%-3.64%
AURHT
61
Neutral
AU$18.38M140.00-3.11%89.13%69.57%
54
Neutral
$5.28B3.29-45.38%2.80%16.77%-0.08%
AUMDR
53
Neutral
AU$52.48M110.00-8.34%-5.27%50.29%
AUOPT
30
Underperform
$738.77M
-24.46%-7.90%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:MDR
MedAdvisor Limited
0.08
-0.36
-81.82%
AU:OPT
Opthea
0.60
0.15
34.53%
AU:ADH
Adairs Ltd.
2.74
1.12
68.62%
AU:RHT
Resonance Health Ltd
0.04
-0.02
-33.33%

MedAdvisor Limited Corporate Events

MedAdvisor Announces Change in Substantial Holder’s Interests
Jun 5, 2025

MedAdvisor Limited has announced a change in the interests of its substantial holder, Guild Group Holdings Limited, which now holds 94,905,130 fully paid ordinary shares. This change reflects a reduction in Guild Group Holdings Limited’s voting power due to non-participation in a capital raising offer, while they participated in an entitlement offer, impacting their voting power from 18% to 15.19%.

The most recent analyst rating on (AU:MDR) stock is a Buy with a A$0.53 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.

Mercer Investments Sells Stake in MedAdvisor
May 20, 2025

MedAdvisor Limited, a company in the healthcare technology sector, is known for its digital medication management solutions. Recently, Mercer Investments (Australia) Limited, acting as the responsible entity of the Mercer Australian Small Companies Fund, has ceased to be a substantial holder in MedAdvisor Limited as of May 16, 2025. This change involved the sale of 2,565,351 shares, potentially impacting MedAdvisor’s shareholder structure and market perception.

The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.

MedAdvisor Limited Announces Quotation of New Securities on ASX
May 19, 2025

MedAdvisor Limited has announced the quotation of 389,420 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of May 20, 2025. This move is part of the company’s strategy to enhance its financial flexibility and potentially strengthen its market position, which could have implications for its stakeholders and operations.

The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.

MedAdvisor Announces Change in Substantial Holder Interests
May 16, 2025

MedAdvisor Limited has announced a change in the interests of its substantial holder, EBOS Group Limited, which is a key player in the healthcare and pharmaceutical distribution industry. The announcement indicates a dilution in EBOS’s voting power from 9.81% to 8.65% due to the issuance of new shares by MedAdvisor, including a recent placement and share purchase plan. This change reflects a strategic adjustment in the company’s shareholder structure, potentially impacting its governance dynamics and stakeholder interests.

The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.

MedAdvisor Limited Announces Quotation of New Securities
May 14, 2025

MedAdvisor Limited has announced the quotation of 26,680,000 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of previously announced transactions and is expected to enhance the company’s financial flexibility, potentially impacting its market positioning positively.

The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.

MedAdvisor Completes Oversubscribed Share Purchase Plan
May 14, 2025

MedAdvisor Limited has successfully completed its Share Purchase Plan (SPP), raising A$2.668 million, exceeding its initial target of A$2 million. This funding will support the company’s strategic initiatives and provide additional working capital, with the new shares set to begin trading on 16 May 2025. The company also plans to hold an Extraordinary General Meeting to approve shares committed by directors in a previous placement.

The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.

MedAdvisor Enters Potential Sale Agreement for ANZ Division
May 9, 2025

MedAdvisor Limited has entered into a non-binding Letter of Intent with a subsidiary of a major multinational software company to sell its ANZ business division and associated intellectual property. The potential transaction, valued at $35 million with an additional earn-out component, could significantly impact MedAdvisor’s operations and market positioning by aligning with a company that has a substantial market capitalization and revenue.

MedAdvisor Initiates Trading Halt Amid Strategic Update
May 7, 2025

MedAdvisor Limited has requested a trading halt on its securities as it prepares to release an announcement regarding a strategic update. This halt is related to a non-binding proposal to acquire its ANZ business division, indicating potential significant changes in its operational focus and market strategy.

MedAdvisor Receives Acquisition Proposal for ANZ Division
May 6, 2025

MedAdvisor Limited has received a non-binding Letter of Intent from a multinational software company to acquire its ANZ business division, which the directors believe offers a materially higher value than the current share price. This proposal aligns with MedAdvisor’s strategic review process aimed at bridging the valuation gap of its ANZ and US business units. The ANZ division recently achieved record revenue, and the potential acquirer plans to continue investing in the business, benefiting pharmacies across Australia. The transaction, subject to due diligence, is expected to be finalized within 5 to 7 weeks.

MedAdvisor Limited Resumes Trading on ASX
May 2, 2025

MedAdvisor Limited, listed on the Australian Securities Exchange (ASX) under the ticker MDR, has announced the lifting of its trading suspension. This follows the release of an announcement concerning the outcome of a Court application under section 1322 of the Corporations Act 2001, which allows the company to resume trading immediately.

MedAdvisor Resumes Trading After Court Approval
May 2, 2025

MedAdvisor Limited has announced that the Federal Court of Australia granted their request to rectify an administrative oversight related to a late lodgement of a cleansing notice for shares issued in a recent placement. Following this court order, MedAdvisor has requested the resumption of trading in its securities, which had been voluntarily suspended. This development is expected to restore normal trading operations and maintain investor confidence.

MedAdvisor Releases 3Q FY25 Investor Update with Cautionary Notes
Apr 30, 2025

MedAdvisor Limited has released an investor presentation update for the third quarter of FY25, emphasizing that the information provided is for general informational purposes and not intended as financial advice or an investment offer. The presentation includes disclaimers about the accuracy and completeness of the information, highlighting the potential risks and uncertainties associated with forward-looking statements, and advises recipients to conduct their own independent assessments.

MedAdvisor Limited Reports 3Q FY25 Financials and Strategic Initiatives
Apr 30, 2025

MedAdvisor Limited reported a significant decline in its financial performance for 3Q FY25, with operating revenue and gross profit nearly halved compared to the previous year. Despite these challenges, the company is actively pursuing strategic initiatives to capitalize on evolving market trends, including cost optimization and restructuring its US operations. The company also completed a $5 million capital raise to support these initiatives, aiming for sustainable growth in FY26.

MedAdvisor to Present 3Q FY25 Results in Upcoming Webinar
Apr 29, 2025

MedAdvisor Limited announced that its CEO, Rick Ratliff, and CFO, Ancila Desai, will present the company’s third-quarter FY25 results in a live webinar on April 30, 2025. This event is significant for stakeholders as it provides insights into the company’s operational performance and strategic direction, potentially impacting its market positioning and investor relations.

MedAdvisor Seeks Voluntary Suspension Amid Court Proceedings
Apr 29, 2025

MedAdvisor Limited has requested a voluntary suspension of its securities from the Australian Securities Exchange (ASX) pending a court application. This action is to ensure that trading does not occur on an uninformed basis while the company seeks to validate a cleansing notice related to share issuance. The suspension will remain until the court’s decision or a further announcement by the company, expected by May 2, 2025.

MedAdvisor Extends Share Purchase Plan Deadline
Apr 28, 2025

MedAdvisor Limited has announced an extension to its Share Purchase Plan (SPP) deadline, moving it from April 30, 2025, to May 9, 2025. This extension aims to provide eligible shareholders additional time to participate and complete their applications, potentially impacting shareholder engagement and investment levels.

MedAdvisor Limited Initiates Trading Halt Pending Key Announcement
Apr 23, 2025

MedAdvisor Limited has requested a trading halt on its securities pending an important announcement related to a Court order under the Corporations Act. This halt will remain until the announcement is made or until normal trading resumes on April 29, 2025. The decision indicates a significant development that could impact the company’s operations or market positioning, though specific details are yet to be disclosed.

MedAdvisor Extends Share Purchase Plan Deadline
Apr 15, 2025

MedAdvisor Limited has announced an extension of its Share Purchase Plan (SPP) deadline from April 17 to April 30, 2025, to provide eligible shareholders additional time to participate. This extension reflects the company’s commitment to engaging its stakeholders and potentially increasing shareholder participation, which may impact its financial strategy and market positioning.

MedAdvisor’s Substantial Holder Increases Stake
Apr 10, 2025

MedAdvisor Limited has reported a change in the substantial holding of Perennial Value Management Limited, which has increased its voting power from 13.33% to 15.03%. This change was facilitated through a series of market transactions involving various financial institutions, indicating an active adjustment in investment strategy. The increase in voting power suggests a stronger influence of Perennial Value Management Limited in MedAdvisor’s corporate decisions, potentially impacting future business strategies and shareholder dynamics.

Jencay Capital Increases Stake in MedAdvisor Limited
Apr 10, 2025

MedAdvisor Limited has announced a change in the substantial holding of its shares by Jencay Capital Pty Limited. Jencay Capital has increased its voting power from 6.21% to 7.24% through market purchases and participation in a placement, acquiring an additional 8,983,390 shares. This change reflects a strategic move by Jencay Capital to strengthen its influence within MedAdvisor, potentially impacting the company’s governance and future strategic decisions.

MedAdvisor Limited Announces New Securities Quotation
Apr 7, 2025

MedAdvisor Limited has announced the application for quotation of 45,750,000 fully paid ordinary securities on the Australian Securities Exchange (ASX), set to be issued on April 8, 2025. This move is part of previously announced transactions and is expected to bolster the company’s financial position, potentially enhancing its market presence and offering stakeholders increased investment opportunities.

MedAdvisor Launches Share Purchase Plan to Boost Shareholder Value
Apr 7, 2025

MedAdvisor Limited has announced the opening of its Share Purchase Plan (SPP) Offer, allowing eligible shareholders to purchase up to $30,000 in fully paid ordinary shares at an issue price of $0.10 per share. This follows a successful placement to institutional investors at the same price, aiming to enhance shareholder value and strengthen the company’s financial position.

MedAdvisor Limited Announces Securities Issue to Bolster Financial Position
Apr 1, 2025

MedAdvisor Limited has announced a proposed issue of 20 million ordinary fully paid securities under a securities purchase plan, with the record date set for March 31, 2025, and the offer closing on April 17, 2025. This move is part of MedAdvisor’s strategy to strengthen its financial position, potentially enhancing its market presence and operational capabilities in the digital healthcare sector.

MedAdvisor Announces Capital Raising to Boost Financial Strength
Apr 1, 2025

MedAdvisor Limited has announced a capital raising initiative through a placement and a share purchase plan to issue new shares to eligible shareholders. This move is expected to strengthen the company’s financial position, potentially enhancing its market presence and operational capabilities in the healthcare technology sector.

MedAdvisor Limited Completes $5 Million Placement Amid Strategic Review
Apr 1, 2025

MedAdvisor Limited has successfully completed a $5 million institutional placement and announced a $2 million Share Purchase Plan, aimed at supporting its strategic growth and cost-optimization initiatives. The company is undergoing a strategic review to maximize shareholder value, with strong interest in its Australian business and several non-binding proposals received. The company anticipates revenue growth and margin expansion in the coming years, alongside significant operational cost savings.

MedAdvisor Limited Initiates Trading Halt for Strategic Announcement
Mar 30, 2025

MedAdvisor Limited has requested a trading halt on its securities pending an announcement related to a capital raising through a placement and an update on its strategic review. This move is likely to impact the company’s financial strategy and market positioning, signaling potential changes that stakeholders should be aware of.

Jencay Capital Boosts Stake in MedAdvisor Limited
Mar 11, 2025

Jencay Capital Pty Limited has increased its stake in MedAdvisor Limited, raising its voting power from 5.11% to 6.21% by purchasing 6,076,578 ordinary shares. This change in substantial holding reflects Jencay Capital’s growing interest in MedAdvisor, potentially impacting the company’s shareholder dynamics and signaling confidence in its market position.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.